Imaging Features of Pulmonary Immune-related Adverse Events
- PMID: 34087477
- DOI: 10.1016/j.jtho.2021.05.017
Imaging Features of Pulmonary Immune-related Adverse Events
Abstract
Pulmonary immune-related adverse events represent rare but potentially severe side effects of immunotherapies. Diagnosis is often challenging, as symptoms and imaging features are not specific and may mimic other lung diseases, thus potentially delaying appropriate patient management. In this setting, an accurate imaging evaluation is essential for a prompt detection and correct management of these drug-induced lung diseases. The purpose of this article is to review the different types of pulmonary immune-related adverse events, describe their imaging characteristics on both high-resolution computed tomography and positron emission tomography/computed tomography and stress their underlying diagnostic challenge by presenting the mimickers.
Keywords: CTLA-4 antigen; Drug-related side effects and adverse reactions; Immunotherapy; Pneumonitis; Programmed cell death 1 receptor.
Copyright © 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
Comment in
-
A Wake-Up Call for Immune Checkpoint Inhibitor-Related Pneumonitis.J Thorac Oncol. 2021 Sep;16(9):1440-1442. doi: 10.1016/j.jtho.2021.06.001. J Thorac Oncol. 2021. PMID: 34425997 No abstract available.
Similar articles
-
Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.Oncologist. 2017 Jan;22(1):70-80. doi: 10.1634/theoncologist.2016-0164. Epub 2016 Aug 17. Oncologist. 2017. PMID: 27534573 Free PMC article. Review.
-
Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update.J Dtsch Dermatol Ges. 2020 Jun;18(6):582-609. doi: 10.1111/ddg.14128. Epub 2020 Jun 3. J Dtsch Dermatol Ges. 2020. PMID: 32489011
-
Immunotherapy-related adverse effects on 18F-FDG PET/CT imaging.Br J Radiol. 2020 Jul;93(1111):20190832. doi: 10.1259/bjr.20190832. Epub 2020 Feb 27. Br J Radiol. 2020. PMID: 32105505 Free PMC article.
-
Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment.J Immunother Cancer. 2020 Jul;8(2):e000952. doi: 10.1136/jitc-2020-000952. J Immunother Cancer. 2020. PMID: 32699182 Free PMC article.
-
What do we know about cancer immunotherapy? Long-term survival and immune-related adverse events.Allergol Immunopathol (Madr). 2019 May-Jun;47(3):303-308. doi: 10.1016/j.aller.2018.04.005. Epub 2018 Jul 6. Allergol Immunopathol (Madr). 2019. PMID: 29983240 Review.
Cited by
-
Radiological assessment of immunotherapy effects and immune checkpoint-related pneumonitis for lung cancer.J Cell Mol Med. 2023 Jul 31;28(5):e17895. doi: 10.1111/jcmm.17895. Online ahead of print. J Cell Mol Med. 2023. PMID: 37525480 Free PMC article. Review.
-
Case report: Pneumonia with clinical symptoms precedes imaging evidence after immune checkpoint inhibitors combined with radiotherapy in lung squamous cell cancer.Front Immunol. 2022 Sep 15;13:998516. doi: 10.3389/fimmu.2022.998516. eCollection 2022. Front Immunol. 2022. PMID: 36189237 Free PMC article.
-
Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review.Front Oncol. 2022 Aug 16;12:911906. doi: 10.3389/fonc.2022.911906. eCollection 2022. Front Oncol. 2022. PMID: 36052257 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
